Phase II Trial on SBRT for Unresectable Liver Metastases: Long-term Outcome and Prognostic Factors of Survival After 5 years of Follow-up

Overview

Journal Radiat Oncol

Publisher Biomed Central

Specialties Oncology
Radiology

Date 2018 Nov 28

PMID 30477560

Citations 42

Authors

Marta Scorsetti

Tiziana Comito

Elena Clerici

Ciro Franzese

Angelo Tozzi

Cristina Iftode

Lucia Di Brina

Pierina Navarria

Pietro Mancosu

Giacomo Reggiori

Antonella Fogliata

Stefano Tomatis

Guido Torzilli

Luca Cozzi

Affiliations

Soon will be listed here.

Abstract

Background: The aim of this study was to evaluate long-term efficacy and survival prognostic factors of stereotactic body radiation therapy (SBRT) for un-resectable liver metastases in patients enrolled in a prospective phase II trial.

Methods And Materials: 5-year local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with un-resectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75Gy in 3 consecutive fractions.

Results: A total of 61 patients with 76 lesions were enrolled, with a median follow-up time of 6.1 years. One, three and 5 year LC rates were 94 ± 3.1%, 78.0 ± 5.9% and 78.0 ± 5.9%, without reaching the median LC time. Median OS was 27.6 months and the survival rates were 85.2 ± 4.5%, 31.1 ± 5.9% and 18.0 ± 4.9% at 1, 3 and 5-year after SBRT, respectively. Univariate analysis showed that favorable primary site (colorectal, breast and gynecological) of metastases (p = 0.001) improved survival. Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1 year from SBRT. No cases of Radiation Induced Liver Disease (RILD) were detected.

Conclusions: Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.

Citing Articles

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N Cancer. 2024; 131(1):e35612.

PMID: 39616467 PMC: 11694557. DOI: 10.1002/cncr.35612.

Stereotactic body radiation therapy for colorectal cancer liver metastases.

Lukovic J, Dawson L J Gastrointest Oncol. 2024; 15(4):1917-1925.

PMID: 39279927 PMC: 11399821. DOI: 10.21037/jgo-22-1183.

The evolving role of radiation therapy as treatment for liver metastases.

Alrabiah K, Liao G, Shen Q, Chiang C, Dawson L J Natl Cancer Cent. 2024; 2(3):183-187.

PMID: 39036451 PMC: 11256533. DOI: 10.1016/j.jncc.2022.06.004.

Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume.

Chang E, Wong F, Chasen B, Erwin W, Das P, Holliday E JNCI Cancer Spectr. 2024; 8(3).

PMID: 38730548 PMC: 11164414. DOI: 10.1093/jncics/pkae037.

Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.

Averbuch I, Moore A, Ludmir E, Markel G, Meirson T Br J Cancer. 2024; 130(12):1929-1935.

PMID: 38710837 PMC: 11183092. DOI: 10.1038/s41416-024-02700-z.

References

Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P . Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009; 29(8):3381-4. View

Fode M, Hoyer M . Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015; 114(2):155-60. DOI: 10.1016/j.radonc.2014.12.003. View

Klement R, Guckenberger M, Alheid H, Allgauer M, Becker G, Blanck O . Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017; 123(2):227-233. DOI: 10.1016/j.radonc.2017.01.013. View

Tomlinson J, Jarnagin W, DeMatteo R, Fong Y, Kornprat P, Gonen M . Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007; 25(29):4575-80. DOI: 10.1200/JCO.2007.11.0833. View

Mendez Romero A, Wunderink W, van Os R, Nowak P, Heijmen B, Nuyttens J . Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys. 2007; 70(5):1447-52. DOI: 10.1016/j.ijrobp.2007.08.058. View

Ahmed K, Caudell J, El-Haddad G, Berglund A, Welsh E, Yue B . Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016; 95(5):1399-1404. PMC: 7771381. DOI: 10.1016/j.ijrobp.2016.03.050. View

Weichselbaum R, Hellman S . Oligometastases revisited. Nat Rev Clin Oncol. 2011; 8(6):378-82. DOI: 10.1038/nrclinonc.2011.44. View

Gillams A, Lees W . Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol. 2009; 19(5):1206-13. DOI: 10.1007/s00330-008-1258-5. View

Goodman B, Mannina E, Althouse S, Maluccio M, Cardenes H . Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases. Pract Radiat Oncol. 2016; 6(2):86-95. DOI: 10.1016/j.prro.2015.10.011. View

10.

Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C . The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015; 141(7):1301-9. DOI: 10.1007/s00432-015-1929-y. View

11.

Mazzola R, Fersino S, Alongi P, Di Paola G, Gregucci F, Aiello D . Stereotactic body radiation therapy for liver oligometastases: predictive factors of local response by F-FDG-PET/CT. Br J Radiol. 2018; 91(1088):20180058. PMC: 6209463. DOI: 10.1259/bjr.20180058. View

12.

Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P . Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys. 2013; 86(2):336-42. DOI: 10.1016/j.ijrobp.2012.12.021. View

13.

Chang D, Swaminath A, Kozak M, Weintraub J, Koong A, Kim J . Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011; 117(17):4060-9. DOI: 10.1002/cncr.25997. View

14.

Adams R, Aloia T, Loyer E, Pawlik T, Taouli B, Vauthey J . Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013; 15(2):91-103. PMC: 3719914. DOI: 10.1111/j.1477-2574.2012.00557.x. View

15.

Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E . Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2014; 141(3):543-53. DOI: 10.1007/s00432-014-1833-x. View

16.

Nordlinger B, Sorbye H, Glimelius B, Poston G, Schlag P, Rougier P . Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008; 371(9617):1007-16. PMC: 2277487. DOI: 10.1016/S0140-6736(08)60455-9. View

17.

Meyer J, Foster R, Lev-Cohain N, Yokoo T, Dong Y, Schwarz R . A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver Metastases. Ann Surg Oncol. 2015; 23(1):218-24. PMC: 4695498. DOI: 10.1245/s10434-015-4579-z. View

18.

Lee M, Kim J, Dinniwell R, Brierley J, Lockwood G, Wong R . Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol. 2009; 27(10):1585-91. DOI: 10.1200/JCO.2008.20.0600. View

19.

Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M . Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006; 244(4):524-35. PMC: 1856551. DOI: 10.1097/01.sla.0000239036.46827.5f. View

20.

Joo J, Park J, Kim J, Yu C, Lim S, Park I . Local Control Outcomes Using Stereotactic Body Radiation Therapy for Liver Metastases From Colorectal Cancer. Int J Radiat Oncol Biol Phys. 2017; 99(4):876-883. DOI: 10.1016/j.ijrobp.2017.07.030. View